Histopathological evaluation of induced pulmonary fibrosis under the effect of montelukast

Pulmonary fibrosis (PF) is an interstitial lung disease leading to scarring of the lung. There are several types as familial pulmonary fibrosis, idiopathic and others associated with non-specific
 
 pneumonia. The most common type which unknown cause. Lung causes changes in histology by disappearance parenchyma, replaced inflammatory infiltrate, mild thickening artery. management included Azathioprine, corticosteroid, N-acetyl cysteinyl 2011 but 2014 this guideline was removed nintedanib pirfenidone. This study used Pirfenidone, standard therapy for treatment montelukast Cysteinyl leukotrienes (CysLT) antagonist binds its receptor (CysLTE4) located on smooth muscle cells respiratory airway causing anti-inflammatory effect inhibition markers TGFβ1. Sixty male rats were divided into five groups,12 each group where control received distilled water gastric gavage, induction bleomycin intratracheally a single dose, pirfenidone 50mg/kg, 20mg/kg combination half dose montelukast. After twenty-eight days after or sacrifice collect organ (lungs) from then placed buffer formalin 10% histopathological study. 14 results show that cause massive parenchyma infiltrate medial artery all groups, normal paranchyma 28 pirfenidone, montelukast, groups.
 In conclusion, groups except return architecture treatment.